Premium
Treatment of acute myeloid leukemia in elderly patients. A retrospective study
Author(s) -
Sebban Catherine,
Archimbaud Eric,
Coiffier Bertrand,
Guyotat Denis,
Maupas Jean,
Fiere Denis,
TreilleRitouet Danièle
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880115)61:2<227::aid-cncr2820610204>3.0.co;2-j
Subject(s) - medicine , myeloid leukemia , chemotherapy , acute myeloblastic leukemia , retrospective cohort study , cytarabine , surgery , performance status , toxicity , leukemia , gastroenterology , pediatrics
In an attempt to rationalize the use of therapy in acute myeloblastic leukemia (AML) in elderly patients, 69 cases of primary AML in patients older than 60 years of age were reviewed retrospectively. Therapy was empirical and 12 patients received supportive care (SC) only, 35 received aggressive chemotherapy (AC), and 22 received low‐dose cytosine arabinoside (LD‐araC). Patients receiving SC only often had a poor Karnofski index and their median survival was 17 days. Aggressive chemotherapy yielded complete remissions (CR) in 48% of the patients, whereas 23% of the patients had resistant disease (RD) and 29% had other failures (OF). Low‐dose araC, which was administered to patients significantly older than those receiving AC, yielded 23% CR, 68% RD, and 9% OF, with important hematologic toxicity in most patients. Median survival was 211 days in patients receiving AC and 235 days in patients treated with LD‐araC. Survival beyond 2 years from diagnosis was noted in the AC group only. A low Karnofski index was the strongest factor in poor prognosis, while age was not a prognostic factor. The initial characteristics of the patients did not allow us to define groups of patients who should be treated by either AC or LD‐araC. We concluded that the decision to treat patients actively should rely more on the patient's general condition and socio‐economical criteria than on age.